Tapinarof Cream 1% Once Daily Improves Patient-reported Outcomes in the Head and Neck Region of Adults with Plaque Psoriasis

George Michael Lewitt,1 Linda Stein Gold,2 Philip M. Brown,4 Katherine Tillman,4 Nancy Fitzgerald,4 Brandon Kirsch,4 Anna M. Tallman,4 Abel D. Jarell5
1Illinois Dermatology Institute, Chicago, IL, USA; 2Henry Ford Health System, Detroit, MI, USA; 3DermAssure, Silver Spring, MD, USA; 4Dermavant Sciences, Inc., Montville, NJ, USA; 5Northwest Dermatology Associates, Portsmouth, NH, USA

INTRODUCTION

- Up to 18% of patients with plaque psoriasis experience lesions in the head and neck region, with the scalp being one of the most commonly affected areas.
- Because of its location, psoriasis affecting the head and neck region has a substantial impact on health-related quality of life (HRQoL), through physical, psychological, and psychosocial dimensions.

OBJECTIVE

- To present patient-reported outcomes from the open-label phase (12 weeks) of a trial of tapinarof cream 1% QD for the treatment of adults with mild to severe plaque psoriasis affecting the head and neck region.

MATERIALS AND METHODS

- In the open-label, multicenter trial, adults with mild to severe plaque psoriasis affecting the head and neck region received tapinarof cream 1% QD for 12 weeks, followed by off-treatment (Figures 1 and 2).

RESULTS

- Baseline Patient Demographics and Disease Characteristics
- Gender: 77 (60.7%) were male and 54 (42.3%) were female.
- Mean age was 56.5 ± 14.1 years.
- Most patients had mild to moderate plaque psoriasis (tPGA=2).

- Changes in Peak Pruritus Numerical Rating Scale (PP-NRS) score for the head and neck region
- Mean PP-NRS score at baseline was 5.8, and 80.6% (n=25/31) had a PP-NRS score of ≥4.
- Rapid improvement in mean PP-NRS score was demonstrated as early as Week 1, with a difference of −1.6 [standard deviation (SD), 2.54] from baseline.

- Changes in Dermatology Life Quality Index (DLQI) score
- Mean DLQI total score was 9.7, indicating a moderate impact of disease on HRQoL.
- Most patients strongly agreed or agreed with questions assessing satisfaction with cosmetic elegance (93.3%) (not greasy), quick absorption (96.7%), and ease of application (93.3%).

- Tolerability
- The most frequent treatment-emergent adverse events (TEAEs) were contact dermatitis, folliculitis, and headache.
- Patient satisfaction data showed a consistent and highly positive perception of tapinarof cream across all relevant parameters, including satisfaction with cosmetic elegance, ease of application, and efficacy.

CONCLUSIONS

- Tapinarof cream 1% (VTAMA®, Dermavant Sciences, Inc.) is a non-steroidal, topical aryl hydrocarbon receptor agonist approved for the treatment of plaque psoriasis.
- In this 12-week, open-label, phase 4 trial (NCT05789576), tapinarof cream 1% QD demonstrated efficacy and was well tolerated in patients with mild to severe plaque psoriasis affecting the head and neck region.

REFERENCES


ACKNOWLEDGMENTS

- The authors thank the participating investigators, sites, and staff members, and acknowledge the contributions of the patients and their families. The authors also wish to thank the members of the steering committee and the trial steering committee.

Figure 2. (A) Proportion of Patients who Achieved >4-point Improvement in PP-NRS (Head and Neck Region), and (B) Mean Improvement in DLQI from Baseline to Week 12 in Patients with Plaque Psoriasis Affecting the Head and Neck Region

Figure 3. Achievement of MCID in DLQI as early as Week 1, and tPGA and PP-NRS Success at Week 12 in a Patient with Plaque Psoriasis Affecting the Head and Neck Region

Figure 4. High Confidence and Satisfaction with Cosmetic Elegance, Ease of Application, and Efficacy of Tapinarof Cream 1% QD (N=31)

Table 1. Baseline Disease Characteristics

Patient-reported outcomes analyses showed a highly positive perception of tapinarof cream across all relevant parameters, including satisfaction with cosmetic elegance, ease of application, and efficacy.

Figure 5. A Qualitative Post Hoc Survey of Patients' Overall Perception of Tapinarof Cream 1% QD

If available

Satis/fied with                In tapinarof                                100.0%                Easily manage                             35.8%
Thick/look and feel in tapinarof                                      96.7%                If available
Satis/fied with                Strongly agree                                10.0%                Coming back to tapinarof
Strongly agree/Agree                     93.3%                Others
Strongly disagree/Disagree                      3.3%                tapinarof
If available

Figure 6. Qualitative Patient-Principal Outcomes at Week 12

- Most patients strongly agreed or agreed with questions assessing satisfaction with cosmetic elegance (93.3%) (not greasy), quick absorption (96.7%), and ease of application (96.7%).
- Patient Satisfaction Questionnaires

Tapinarof feels good on skin
86.7%
Tapinarof is effective for my condition
70.4%
Tapinarof feels comfortable on the skin
68.2%
Tapinarof feels easy to apply
62.2%
Tapinarof works for me
41.7%
Tapinarof controls pruritus
68.9%